Core Viewpoint - The article emphasizes the significant therapeutic potential of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), highlighting its multifaceted benefits beyond glucose control, including improvements in physical function and quality of life [4][5]. Research Objectives - The study aims to analyze whether the efficacy of Semaglutide is consistent across different clinical characteristics in patients with type 2 diabetes and PAD, focusing on variables such as diabetes duration, body mass index (BMI), HbA1c levels, and concurrent use of other diabetes medications [7][8]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, employing a randomized, double-blind design over 52 weeks to assess the effects of Semaglutide compared to a placebo [10]. Core Assessment Indicators - Key evaluation metrics included the maximum walking distance (MWD) and pain-free walking distance (PFWD) after 52 weeks, with subgroup analyses based on diabetes duration, BMI, blood glucose control, and concurrent medication use [12]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient subgroups, demonstrating consistent efficacy regardless of diabetes duration, BMI, or blood glucose control [13][14]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD appeared to operate through mechanisms independent of weight loss and glucose reduction [14]. Key Findings - The study concluded that Semaglutide offers a robust treatment option for patients with PAD and type 2 diabetes, with efficacy unaffected by patient characteristics such as duration of diabetes, BMI, or concurrent medication use [15][16]. - The findings suggest that Semaglutide may improve endothelial function, enhance microcirculation, and exert anti-inflammatory effects, contributing to its therapeutic benefits [16].

Core Viewpoint - The article emphasizes the significant therapeutic potential of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), highlighting its multifaceted benefits beyond glucose control and weight loss [3][10]. Research Objectives - The study aims to analyze whether the efficacy of Semaglutide is consistent across different clinical characteristics in patients with type 2 diabetes and PAD, focusing on key variables such as diabetes duration, body mass index (BMI), HbA1c levels, and concurrent medication use [5][8]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, employing a randomized, double-blind design over 52 weeks to assess the effects of Semaglutide compared to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments of pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient subgroups, indicating a stable therapeutic effect regardless of patient characteristics [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD appeared to operate through independent mechanisms [11][12]. Safety Profile - The safety profile of Semaglutide was found to be comparable to that of the placebo, with no new safety concerns identified, and common gastrointestinal reactions and hypoglycemia were evenly distributed among subgroups [13]. Conclusion - Semaglutide is positioned as a breakthrough treatment option for patients with type 2 diabetes and PAD, demonstrating efficacy that extends beyond traditional mechanisms, including improvements in endothelial function and anti-inflammatory effects [16].